News and Press Releases
Abacus Medicine Pharma Services and Mirum Pharmaceuticals Sign Partnership Agreement for the Commercialization of Livmarli in the Nordics
10 September 2024 -- Copenhagen, Denmark -- Abacus Medicine Pharma Services (‘Abacus’) announces the signing of a partnership agreement with Mirum Pharmaceuticals, Inc. (‘Mirum’) for the commercialization of LIVMARLI® (maralixibat)...
Category: Drug Delivery, Other, Pharmaceutical
Posted: September 10, 2024
Kalvebod Brygge 35 1560 Copenhagen V Denmark
Research Integrity, AI Applications for Drug Discovery Covered in Opening and Closing Plenaries at PharmSci 360Registration for Now Open
Arlington, VA—AAPS is excited to announce the opening and closing plenary speakers for the 2024 PharmSci 360, taking place October 20-23 in Salt Lake City, Utah. PharmSci 360 opens on...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024
2107 Wilson Blvd #200 Arlington, VA 22201
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024
PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...
Category: BioManufacturing
Posted: September 9, 2024
Epsilogen completes £12.5 million Series B financing expansion
Expansion brings total Series B funds raised to £43.25 million Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE 9 September 2024 -- London, UK --...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2024
CPHI Milan Announce Pharma Award finalists
Finalists span 14 categories including awards for future leaders, women of the year and ‘at the heart of pharma’ 06 September 2024 – MIlan, Italy – CPHI Milan (8-10 October 2024)...
Category: Pharmaceutical
Posted: September 9, 2024
RYBREVANT▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 8, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Braunform is a KLIMAfit Company
Braunform GmbH, based in Bahlingen and Endingen a. K., Germany, has successfully participated in the KLIMAfit program and received an award from the Baden-Württemberg Ministry for the Environment, Climate Protection...
Category: Logistics
Posted: September 6, 2024
Rentschler Biopharma introduces new lentiviral vector manufacturing toolbox for advanced therapies
Expanded service offering client ready at company’s site in Stevenage, UK Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral...
Category: BioManufacturing, Pharmaceutical Contractors
Posted: September 5, 2024
Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
Castres, France, August 30, 2024 – Pierre Fabre Laboratories announced today that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult...
Category:
Posted: September 5, 2024
1 Avenue d'Albi, Castres, Occitanie 81100, Tarn, France.
Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK
2 September 2024 – Oxford, UK – Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding...
Category: Drug Discovery
Posted: September 5, 2024
The Sherard Building, Edmund Halley Road, Oxford Science Park, Oxford. OX4 4DQ
Expert Speaker Line-Up Revealed for Industry-Leading RBQM Event
CluePoints Supports Launch of RBQMLive 2024 as Premier Event Sponsor 4 September 2024 -- Pennsylvania, US -- CluePoints, the premier sponsor of RBQMLive and provider of Risk-Based Quality Management (RBQM) and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 4, 2024
Sustainability vs Suitability: Challenging Conventional Thinking in Temperature-Controlled Packaging Design
ISTA European Packaging Symposium, Frankfurt 8-9 October 2024 Maarten Kleverlaan to address sustainability in packaging at International Safe Transit Association Symposium Innovative approaches to temperature-controlled packaging design Emphasising financial and...
Category: Manufacturing and Packing
Posted: September 4, 2024
The countdown is on as the PPMA Show prepares to open its doors
The start of the highly anticipated 2024 PPMA Show is nearly here. The show will take place once again at the NEC Birmingham from 24 to 26 September. The UK’s...
Category: Pharmaceutical
Posted: September 3, 2024
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 30, 2024
